These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33298591)

  • 1. Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining
    Van De Vyver AJ; Weinzierl T; Eigenmann MJ; Frances N; Herter S; Buser RB; Somandin J; Diggelmann S; Limani F; Lehr T; Bacac M; Walz AC
    Mol Cancer Ther; 2021 Feb; 20(2):357-366. PubMed ID: 33298591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
    Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
    Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
    Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
    Gonzalez-Exposito R; Semiannikova M; Griffiths B; Khan K; Barber LJ; Woolston A; Spain G; von Loga K; Challoner B; Patel R; Ranes M; Swain A; Thomas J; Bryant A; Saffery C; Fotiadis N; Guettler S; Mansfield D; Melcher A; Powles T; Rao S; Watkins D; Chau I; Matthews N; Wallberg F; Starling N; Cunningham D; Gerlinger M
    J Immunother Cancer; 2019 Apr; 7(1):101. PubMed ID: 30982469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
    Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
    Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing the Design and Geometry of T Cell-Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer.
    Elsayed A; Plüss L; Nideroest L; Rotta G; Thoma M; Zangger N; Peissert F; Pfister SK; Pellegrino C; Dakhel Plaza S; De Luca R; Manz MG; Oxenius A; Puca E; Halin C; Neri D
    Mol Cancer Ther; 2024 Jul; 23(7):1010-1020. PubMed ID: 38638035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
    Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
    Geiger M; Stubenrauch KG; Sam J; Richter WF; Jordan G; Eckmann J; Hage C; Nicolini V; Freimoser-Grundschober A; Ritter M; Lauer ME; Stahlberg H; Ringler P; Patel J; Sullivan E; Grau-Richards S; Endres S; Kobold S; Umaña P; Brünker P; Klein C
    Nat Commun; 2020 Jun; 11(1):3196. PubMed ID: 32581215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PET-Tracer
    Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
    Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.
    Kroll KT; Mata MM; Homan KA; Micallef V; Carpy A; Hiratsuka K; Morizane R; Moisan A; Gubler M; Walz AC; Marrer-Berger E; Lewis JA
    Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2305322120. PubMed ID: 37603766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
    Dudal S; Hinton H; Giusti AM; Bacac M; Muller M; Fauti T; Colombetti S; Heckel T; Giroud N; Klein C; Umaña P; Benincosa L; Bachl J; Singer T; Bray-French K
    J Immunother; 2016 Sep; 39(7):279-89. PubMed ID: 27404941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The target antigen determines the mechanism of acquired resistance to T cell-based therapies.
    Martínez-Sabadell A; Morancho B; Rius Ruiz I; Román Alonso M; Ovejero Romero P; Escorihuela M; Chicote I; Palmer HG; Nonell L; Alemany-Chavarria M; Klein C; Bacac M; Arribas J; Arenas EJ
    Cell Rep; 2022 Oct; 41(3):111430. PubMed ID: 36261015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes.
    Kuwahara M; Kuroki M; Arakawa F; Senba T; Matsuoka Y; Hideshima T; Yamashita Y; Kanda H
    Anticancer Res; 1996; 16(5A):2661-7. PubMed ID: 8917366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
    Cremasco F; Menietti E; Speziale D; Sam J; Sammicheli S; Richard M; Varol A; Klein C; Umana P; Bacac M; Colombetti S; Perro M
    PLoS One; 2021; 16(1):e0241091. PubMed ID: 33406104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.
    Sánchez J; Nicolini V; Fahrni L; Waldhauer I; Walz AC; Jamois C; Fowler S; Simon S; Klein C; Umaña P; Friberg LE; Frances N
    AAPS J; 2022 Oct; 24(6):106. PubMed ID: 36207642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies.
    Kerns SJ; Belgur C; Petropolis D; Kanellias M; Barrile R; Sam J; Weinzierl T; Fauti T; Freimoser-Grundschober A; Eckmann J; Hage C; Geiger M; Ng PR; Tien-Street W; Manatakis DV; Micallef V; Gerard R; Bscheider M; Breous-Nystrom E; Schneider A; Giusti AM; Bertinetti-Lapatki C; Grant HS; Roth AB; Hamilton GA; Singer T; Karalis K; Moisan A; Bruenker P; Klein C; Bacac M; Gjorevski N; Cabon L
    Elife; 2021 Aug; 10():. PubMed ID: 34378534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.